Bausch Health Companies Inc (BHC)vsViatris Inc (VTRS)
BHC
Bausch Health Companies Inc
$5.37
+2.09%
HEALTHCARE · Cap: $1.89B
VTRS
Viatris Inc
$15.88
-0.13%
HEALTHCARE · Cap: $19.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 38% more annual revenue ($14.56B vs $10.53B). VTRS leads profitability with a -2.0% profit margin vs -11.5%. BHC appears more attractively valued with a PEG of 0.01. BHC earns a higher WallStSmart Score of 69/100 (B-).
BHC
Strong Buy69
out of 100
Grade: B-
VTRS
Buy50
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 44 in profit
Earnings expanding 1368.0% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 20.6%
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Distress zone — elevated risk
Currently unprofitable
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : BHC
The strongest argument for BHC centers on PEG Ratio, Return on Equity, EPS Growth. Revenue growth of 11.7% demonstrates continued momentum. PEG of 0.01 suggests the stock is reasonably priced for its growth.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : BHC
The primary concerns for BHC are Market Cap, Altman Z-Score, Profit Margin.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
VTRS carries more volatility with a beta of 0.90 — expect wider price swings.
BHC is growing revenue faster at 11.7% — sustainability is the question.
VTRS generates stronger free cash flow (348M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BHC scores higher overall (69/100 vs 50/100) and 11.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bausch Health Companies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Bausch Health Companies Inc. develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology and dermatology. The company is headquartered in Laval, Canada.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?